Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide
Encouraged by evidence of the impact that its diabetes drug semaglutide can have on obesity, with patients shedding an average of 16% of their weight in a mid-stage study, top researchers at Novo Nordisk today unveiled an ambitious late-stage strategy to make their mark in a tough, but potentially blockbuster market.
In an R&D update during its Capital Markets Day at its HQ near Copenhagen, investigators for the company said they will recruit 4,500 patients for a Phase IIIa obesity trial for semaglutide, a GLP-1 drug now up for a likely near-term approval at the FDA. And they plan to launch the 68-week study next year, alongside a “landmark” cardiovascular outcomes study with 12,500 people enrolled.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.